Celldex Therapeutics CLDX Income Statement (2010-2026)

NASDAQ CLDX
$30.76 -0.48 (-1.52%)
As of: Nov 10, 2026 · 2:43 PM EST
Reported Financials

Celldex Therapeutics Quarterly Income Statement

Periods 66 quarters
Latest Sep 2026

Celldex Therapeutics reported net income of -$75.56M for the quarter ended Sep 2026. This income statement covers 66 quarters of results from Jun 2010 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Income StatementIncome Statement Jun2010 Sep2010 Dec2010 Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Revenue & cost
Revenue
0.33M0.17M0.16M0.41M1.61M0.97M0.27M1.52M4.13M0.16M2.50M3.19M1.18M0.70M0.73M0.12M0.02M0.02M
Operating items
Amortization - Intangibles
Research & DevelopmentR&D
14.68M17.06M20.73M21.57M22.90M26.80M26.25M34.54M30.43M31.66M39.69M45.26M46.94M52.61M54.20M62.93M75.33M73.00M67.54M67.41M
Selling, General & AdministrativeSG&A
6.24M6.91M7.15M6.53M6.60M6.64M7.22M8.22M8.83M9.10M9.13M10.05M10.26M10.82M10.39M10.69M11.94M11.45M13.10M14.84M
Other Operating ExpensesOther Opex
0.21M0.54M-8.67M-12.50M
Operating ExpensesOpex
20.67M23.43M36.56M28.10M29.50M33.44M33.47M42.76M51.76M40.76M48.82M55.32M57.20M63.43M64.59M73.62M87.27M84.45M80.65M82.25M
Operating IncomeOp. Inc
-20.34M-23.26M-36.40M-27.70M-27.89M-32.47M-33.21M-41.24M-47.63M-40.61M-46.32M-52.13M-56.03M-62.74M-63.86M-73.62M-87.15M-84.44M-80.62M-82.25M
Non-operating items
Non Operating Interest Expenses
Goodwill impairment chargesGoodwill Impair.
Gains (Losses) on Sale of Assets & InvestmentsGains on Sales
Interest & Investment IncomeInt & Inv Inc
0.19M0.21M0.39M0.91M1.40M3.11M2.70M2.98M4.32M7.80M10.48M10.01M8.94M8.94M7.26M6.57M5.84M5.75M7.12M6.69M
Non Operating IncomeNon Op. Inc.
Net income details
EBIT
-20.34M-23.26M-36.40M-27.70M-27.89M-32.47M-33.21M-41.24M-47.63M-40.61M-46.32M-52.13M-56.03M-62.74M-63.86M-73.62M-87.15M-84.44M-80.62M-82.25M
EBT
-20.15M-23.05M-36.00M-26.78M-26.49M-29.36M-30.50M-38.26M-43.31M-32.81M-35.84M-42.12M-47.09M-53.80M-56.60M-67.04M-81.32M-78.69M-73.50M-75.56M
Tax ProvisionsTaxes
Income After Tax
-20.15M-23.05M-36.00M-26.78M-26.49M-29.36M-30.50M-38.26M-43.31M-32.81M-35.84M-42.12M-47.09M-53.80M-56.60M-67.04M-81.32M-78.69M-73.50M-75.56M
Income from Continuing OperationsIncome (Continuing)
-20.15M-23.05M-36.00M-26.78M-26.49M-29.36M-30.50M-38.26M-43.31M-32.81M-35.84M-42.12M-47.09M-53.80M-56.60M-67.04M-81.32M-78.69M-73.50M-75.56M
Consolidated Net IncomeConsol Net Inc.
-20.15M-23.05M-36.00M-26.78M-26.49M-29.36M-30.50M-38.26M-43.31M-32.81M-35.84M-42.12M-47.09M-53.80M-56.60M-67.04M-81.32M-78.69M-73.50M-75.56M
Income towards Parent CompanyParent Net Inc
-20.15M-23.05M-36.00M-26.78M-26.49M-29.36M-30.50M-38.26M-43.31M-32.81M-35.84M-42.12M-47.09M-53.80M-56.60M-67.04M-81.36M-78.69M-73.50M-75.56M
Net Income towards Common StockholdersNet Income
-20.15M-23.05M-36.00M-26.78M-26.49M-29.36M-30.50M-38.26M-43.31M-32.81M-35.84M-42.12M-47.10M-53.80M-56.60M-67.04M-81.36M-78.69M-73.50M-75.56M
Additional items
EPS (Basic)
-0.47-0.49-0.77-0.57-0.56-0.62-0.65-0.81-0.89-0.56-0.54-0.64-0.73-0.81-0.85-1.01-1.22-1.18-0.94-0.96
EPS (Diluted)
-0.47-0.49-0.77-0.57-0.56-0.62-0.65-0.81-0.89-0.56-0.54-0.64-0.73-0.81-0.85-1.01-1.22-1.18-0.94-0.96
Shares Outstanding
42.87M46.74M46.76M46.92M46.89M47.21M47.25M47.26M48.45M58.87M66.02M66.29M64.40M66.38M66.39M66.42M66.42M66.57M77.84M78.53M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
42.87M46.74M46.76M46.92M46.89M47.21M47.25M47.26M48.45M58.87M66.02M66.29M64.40M66.38M66.39M66.42M66.42M66.57M77.84M78.53M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
46.73M46.75M46.76M47.10M47.20M47.24M47.25M47.26M55.88M65.91M66.28M66.34M66.37M66.38M66.39M66.45M66.55M66.57M78.50M78.53M
EBITDA
-19.56M-22.45M-35.66M-27.03M-27.21M-31.75M-32.45M-40.47M-46.87M-39.83M-45.52M-51.34M-55.21M-61.87M-62.98M-72.79M-86.34M-83.58M-79.72M-81.09M
Interest ExpensesInt Expense

Celldex Therapeutics Income Statement API

Pull Celldex Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=CLDX&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY